Thermo Fisher Scientific price to book ratio TMO
Market value divided by the book value of the company's net assets, since 2009.
- Today, Oct 23, 2026
- 4.5×
- 10-year median
- 4.3×
- Against its 10-year history
- 57th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 2.6× to 6.8×
- Peer median
- 5.1×
Thermo Fisher Scientific's price to book ratio is 4.5× as of Oct 23, 2026.
That is above its ten-year median of 4.3×, close to the middle of its last ten years.
Over that time it ranged from 2.6× in Dec 2016 to 6.8× in Dec 2021.
The median for 9 diagnostics and research stocks of a similar size is 5.1×.
Price to book ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.5× | 3.1× | 4.8× |
| 2025 | 4.3× | 3.0× | 4.7× |
| 2024 | 4.1× | 4.0× | 5.1× |
| 2023 | 4.5× | 3.8× | 5.3× |
| 2022 | 5.0× | 4.5× | 6.2× |
| 2021 | 6.8× | 5.0× | 6.8× |
| 2020 | 5.8× | 3.7× | 6.6× |
| 2019 | 4.5× | 3.3× | 4.5× |
| 2018 | 3.3× | 3.2× | 3.7× |
| 2017 | 3.1× | 2.6× | 3.4× |
| 2016 | 2.6× | 2.4× | 3.0× |
| 2015 | 2.7× | 2.3× | 2.8× |
| 2014 | 2.5× | 2.2× | 2.9× |
| 2013 | 2.4× | 1.5× | 2.4× |
| 2012 | 1.5× | 1.2× | 1.5× |
| 2011 | 1.1× | 1.1× | 1.6× |
| 2010 | 1.4× | 1.1× | 1.5× |
| 2009 | 1.3× | 1.2× | 1.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Thermo Fisher Scientific's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| TMOThermo Fisher Scientific | 4.5× |
| DHRDanaher | 3.1× |
| AAgilent Technologies | 6.6× |
| IQVIQVIA | 7.5× |
| WATWaters | 2.9× |
| IDXXIDEXX Laboratories | 27.4× |
| ILMNIllumina | 14.3× |
| MTDMettler-Toledo International | n/m |
| DGXQuest Diagnostics | 3.6× |
| LHLabcorp | 3.1× |
| Peer median | 5.1× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Thermo Fisher Scientific
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.